1. AB0546 Clinical and functional remission based on newly defined ACR/EULAR remission criteria achieved with tocilizumab in patients with rheumatoid arthritis. (23rd January 2014) Authors: Hanami, K.; Saito, K.; Tasaka, H.; Tanaka, Y. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 669 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0066 Behavior of the multi-biomarker disease activity (vectra da algorithm) score and components in patients with rheumatoid arthritis treated with tocilizumab. (23rd January 2014) Authors: Hanami, K.; Hirata, S.; Tasaka, H.; Li, W.; Bolce, R.; Sasso, E. H.; Defranoux, N. A.; Yamaoka, K.; Saito, K.; Tanaka, Y. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A391 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0190 CDAI is a predictor of physical function and bone destruction at week 52 in RA patients. (23rd January 2014) Authors: Hanami, K.; Saito, K.; Tasaka, H.; Tanaka, Y. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 376 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗